VKTX · Viking Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $32.19
Note written ·
Price against the kill line
9.2% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $32.19, on record since 11 November 2026. The shares are down 13.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $32.19, just over the 200-day average of closes, which would show the shares leading the S&P 500. A disclosed VANQUISH topline that matches or beats the Phase 2 weight-loss profile would also show the case wrong.
Research onlyNot in the portfolio.
Last catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 29 October 2026
- Revenue, latest quarter ($M)
- 0.0
- Net cash, cash less debt ($M)
- 709
All filed numbers
What Viking Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) |
|---|---|---|
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −627 | −183 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +5.1 |
| Operating cash flow ($M) | −463 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 960 |
| Debt ($M) convertible debt | 251 |
| Net cash, cash less debt ($M) | 709 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 589 |
| Market value ($M) | 3,726 |
| Enterprise value, market value plus net debt ($M) | 3,017 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 6.3 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 20.0% of shares outstanding sold short, 4.4 days of average trading to cover, −1.5% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $150K | $18.3M |
The thesis
Viking Therapeutics is more likely to lag the S&P 500 over the next three months. Its $960 million cash balance at 30 September 2026 funds the obesity Phase 3 trials, but no pivotal efficacy result is scheduled before 2027, so financing sentiment and competitor news drive the shares until then. The ObesityWeek posters on 15 November 2026 add trial detail, not efficacy.
The shares closed at $27.58 on 12 November 2026. That is 36.1% below the 52-week high of $43.15 (intraday, 12 November 2025) and well under the $35 price of the 24 September 2026 equity offering. The three-month change is –16.9%, from $33.19 on 14 August 2026.
Viking reported third-quarter results on 28 October 2026. The net loss was $183.2 million, or $1.55 per share, against $90.8 million, or $0.81 per share, a year earlier. Benzinga reported the loss missed the $1.07 per-share analyst estimate. Research and development spending rose to $166.8 million from $90.0 million.
The report carried no new efficacy data. The closing low of $24.21 came on 26 October 2026, two days before the report, and the shares have since recovered to $27.58, which is still below both the 50-day and 200-day averages.
Bullish and bearish views on Viking Therapeutics, Inc.
The bull case on Viking Therapeutics, Inc. (VKTX), in brief: cash covers the Phase 3 programs. The bear case: losses are widening fast.
Bull case
- Cash covers the Phase 3 programs. Viking reported $960 million in cash, equivalents and short-term investments at 30 September 2026, up from $706 million at 31 December 2025 (Viking release, 28 October 2026). The increase reflects the September financing.
- Injectable pivotal trials enrolled quickly. VANQUISH-1 enrolled about 4,500 patients in about five months and VANQUISH-2 about 1,000 in about nine months. Viking expects both studies to be completed in 2027.
- Oral Phase 3 is underway. SUNRISE-1 and SUNRISE-2 each target 560 adults on once-daily dosing for 68 weeks (Viking release, 28 October 2026).
- Analysts remain at Buy with far higher targets. Benzinga reported on 31 October 2026 that Canaccord Genuity maintained Buy and raised its price target to $118, against a $27.58 close on 12 November 2026.
- More data is scheduled. Viking announced on 9 November 2026 two ObesityWeek posters, one on VANQUISH-2 baseline characteristics and one on Phase 2 VENTURE obesity-severity and cardiometabolic results. Part 2 of the maintenance study, with about 195 adults, reports in 2027.
Bear case
- Losses are widening fast. The nine-month 2026 net loss was $469.5 million against $202.0 million a year earlier. General and administrative expense reached $20.3 million in the third quarter from $8.6 million, which Viking tied partly to early commercial infrastructure.
- Shares sit below the offering price. Viking priced 7,857,143 common shares at $35 and $225 million of 2.00% convertible notes due 2032 on 24 September 2026. The shares closed at $27.58 on 12 November 2026.
- No pivotal efficacy result before 2027. Viking expects the VANQUISH studies to complete in 2027 and has given no topline date. The extension studies start in the first quarter of 2027, with results in 2028.
- Maintenance evidence is early. The 22 September 2026 study reported 90% weight-loss retention in the combined every-other-week group against 61% for placebo-switch. Weight change was an exploratory endpoint in a study designed for safety, tolerability and pharmacokinetics.
- The trend is negative. The shares closed at $27.58 against a 50-day average of $29.42 and a 200-day average of $32.18 as of 12 November 2026 (adjusted daily closes).
Price setup
The shares closed at $27.58 on 12 November 2026, up from $25.79 on 5 November 2026. The 52-week closing low is $24.21 on 26 October 2026.
The 50-day average of closes is $29.42 and the 200-day average is $32.18, both as of 12 November 2026. The shares sit under both, and the 200-day average is the nearest level that would mark a change in the three-month trend.
The $35 offering price is the main overhead reference. Buyers in the September offering are underwater at the current close.
No earnings date falls inside the next 30 days. Viking's scheduled events are the ObesityWeek posters, which present baseline and Phase 2 data already in hand.
Catalysts ahead
- ~31 December 2026 (est.): Expected completion of the VK3019 single-ascending-dose Phase 1 study (company guidance: the fourth quarter of 2026). Shows progress in the amylin program, which sits behind VK2735 in the pipeline.
Elapsed catalysts
- 14 November 2026: ObesityWeek in Washington, D.C. runs to 17 November 2026; Viking's VANQUISH-2 baseline-characteristics poster is in the session on 15 November 2026. Adds detail on trial populations and existing Phase 2 data; no pivotal efficacy result is expected. (passed)
What would change the view
A daily close above $32.19, just over the 200-day average of closes, which would show the shares leading the S&P 500. A disclosed VANQUISH topline that matches or beats the Phase 2 weight-loss profile would also show the case wrong.
What it trades with
Viking trades with other obesity-drug developers and with large-cap GLP-1 leaders, so competitor data and pricing news can move the shares without any Viking event. Biotech financing conditions matter as well, since the company has no revenue. The shares are not tied to the broader Nasdaq 100 AI trade.
The evidence, claim by claim (8)
- Cash, equivalents and short-term investments were $960 million at 30 September 2026 ($677.6 million cash plus $282.2 million short-term investments), up from $706 million at 31 December 2025. Viking third-quarter 2026 release · as of
- Third-quarter net loss was $183.2 million, or $1.55 per share, against $90.8 million, or $0.81 per share, a year earlier; research and development expense was $166.8 million. Viking third-quarter 2026 release · as of
- VANQUISH-1 enrolled about 4,500 patients in about five months and VANQUISH-2 about 1,000 in about nine months; Viking expects both studies to be completed in 2027. Viking third-quarter 2026 release · as of
- SUNRISE-1 and SUNRISE-2 oral VK2735 Phase 3 trials are underway, each targeting 560 adults on once-daily dosing for 68 weeks. Viking third-quarter 2026 release · as of
- The third-quarter loss of $1.55 per share missed the $1.07 per-share analyst estimate. Benzinga · as of
- Canaccord Genuity maintained Buy on Viking and raised its price target to $118. Benzinga · as of
- Viking announced two ObesityWeek posters: baseline characteristics of the Phase 3 VANQUISH-2 trial (session on 15 November 2026) and VK2735 effects on obesity severity and cardiometabolic parameters from the Phase 2 VENTURE study. Viking announcement, 9 November 2026 · as of
- The shares closed at $27.58 on 12 November 2026, down 16.9% over three months from $33.19 on 14 August 2026. Adjusted daily closes · as of
Sources
Related · shared themes
VERU
Veru
Veru's case rests on whether its oral drug enobosarm preserves lean mass alongside semaglutide; the PLATEAU 32-week interim, guided to…
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…